Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest update is out from Aptevo Therapeutics ( (APVO) ).
On February 11, 2025, Aptevo Therapeutics released an investor presentation detailing its current drug pipeline, showcasing its promising therapeutic candidates aimed at high-value oncology markets. The presentation highlighted ongoing clinical programs, including the RAINIER Phase 1b/2 trial for mipletamig, which displayed promising safety and efficacy results in treating acute myeloid leukemia (AML) patients. The diversified pipeline includes multiple candidates with the potential to address various solid malignancies, supporting Aptevo’s strategic growth and partnership opportunities.
More about Aptevo Therapeutics
Aptevo Therapeutics Inc. operates in the biotechnology industry, focusing on developing bispecific antibody therapeutics. The company’s primary products include clinical candidates like mipletamig and ALG.APV-527 and preclinical candidates such as APVO711, APVO603, and APVO442, targeting hematologic and solid tumor malignancies with significant market potential.
YTD Price Performance: -14.44%
Average Trading Volume: 207,386
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $5.83M
For detailed information about APVO stock, go to TipRanks’ Stock Analysis page.
